Biocon Biologics has a long-term commitment to biosimilars. That is the message that came across clearly from the firm’s chief commercial officer for advanced markets, Matt Erick, as he spoke to Generics Bulletin about how competition in the US biosimilar was a “marathon” that is “not going to be won in the short term.”
The company recently completed the integration of Viatris’ North American operations following Biocon’s landmark $3